Posted by Michael Wonder on 24 Feb 2021
Health Canada approves Dupixent (dupilumab) as the first biologic for the treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years
23 February 2021 - Dupixent is the only biologic medicine approved to treat atopic dermatitis for this patient population.
Sanofi Canada announced today that Health Canada has approved Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis in children aged six to 11 years whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
